Prospective Evaluation of the Clinical Profile and Treatment Outcomes of Proximal Humerus Fractures. (SPHEER)
With an ageing population, fragility fractures secondary to osteoporosis are on a increasing trend. Proximal humerus fractures are common fractures which account for a significant proportion of these fragility fractures. They significantly affect patients function and independence particularly in the elderly.
Currently, treatment options range from conservative treatment with an arm sling to fixation either with plates or intramedullary devices to arthroplasty ranging from a hemiarthroplasty to the latest reverse shoulder arthroplasty. While is there has been a global trend towards surgical treatment for such fractures, there is significant controversy regarding the best treatment with many studies reporting disappointing functional outcomes including residual shoulder pain, limitation in shoulder motion and decreased quality of life regardless of treatment option selected.
In this day and age where healthcare cost is a big concern both at the individual patient level but at a government level as well, evaluating the cost effectiveness of treatment becomes essential as well. Currently in Singapore, there have been a significant trend of an increased use of surgical treatment of proximal humerus fractures however we have very little data in our local context not only to evaluate the clinical effectiveness but also the cost effectiveness of surgical treatment in comparison to conservative treatment.
The primary aim of the study is
To understand the epidemiology and prognostic factors for proximal humerus fractures
- Incidence
- Health service utilization
- clinical and functional outcomes
- To estimate the relative cost-effectiveness of surgical vs non-surgical treatment pathways for managing patients with proximal humerus fractures.
We hypothesize that surgical fixation of the proximal humerus is both clinically and cost effective
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Contato de estudo
- Nome: Bryan Tan
- Número de telefone: 63577713
- E-mail: bryan_tan@whc.sg
Locais de estudo
-
-
-
Singapore, Cingapura
- Recrutamento
- Tan Tock Seng Hospital
-
Contato:
- Bryan Tan
- Número de telefone: 63577713
- E-mail: bryan_tan@whc.sg
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age 21 years old and above
- Radiologically confirmed proximal humerus fracture
- Within 3 weeks of their injury
Exclusion Criteria:
- Open fracture
- Mentally incompetent patients
- Co-morbidities precluding anaesthesia
- Severe soft tissue compromise
- Neurovascular compromise
- Pathological fracture other than osteoporosis
- Surgery delayed > 3 weeks
- Pregnancy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Constant Shoulder Score - change over 6 weeks, 3, 6, 12 months
Prazo: Assessed at baseline, 6 weeks, 3 months, 6 months, 12 months
|
To evaluate the clinical outcomes over time by comparing the change in constant shoulder score over a period of 1 year. The Constant Shoulder Score is used to assess the level of pain and the patient's ability to carry out normal daily activities. Constant score of the unaffected shoulder was also assessed at baseline to compare the function between the two shoulders. |
Assessed at baseline, 6 weeks, 3 months, 6 months, 12 months
|
|
Oxford Shoulder Score - change over 6 weeks, 3, 6, 12 months
Prazo: Assessed at baseline, 6 weeks, 3 months, 6 months, 12 months
|
A 12-item patient-report questionnaire developed to evaluate the outcome of shoulder surgery, excluding surgery for instability.
The OSS contains two subscales, pain and activities of daily living.
Each responses is of a 0-4 scoring format with a higher score representing better function.
Hence, the highest possible total score is 48 and a higher score represents a better outcome.
|
Assessed at baseline, 6 weeks, 3 months, 6 months, 12 months
|
|
QuickDASH scoring - change over 6 weeks, 3, 6, 12 months
Prazo: Assessed at baseline, 6 weeks, 3 months, 6 months, 12 months
|
This score is a subset of 11 items from the 30-item DASH and is a self-reported questionnaire in which the response options are presented as 5-point Likert scales.
At least 10 of the 11 items must be completed for a score to be calculated and the scores range from 0 (no disability) to 100 (most severe disability).
|
Assessed at baseline, 6 weeks, 3 months, 6 months, 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
EQ5D-5L - change over 6 weeks, 3, 6, 12 months
Prazo: Assessed at baseline, 6 weeks, 3 months, 6 months, 12 months
|
EuroQol-5 Dimensions (EQ-5D) consists of 2 dimensions, the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
The patient is asked to indicate his/her health state by selecting the most appropriate statement in each of the five dimensions.
This decision results in a 1-digit number that expresses the level selected for that dimension.
The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.
The VAS will be used as a quantitative measure of health outcome.
|
Assessed at baseline, 6 weeks, 3 months, 6 months, 12 months
|
|
Costing questionnaire
Prazo: Assessed at 6 weeks, 3 months, 4.5 months, 6 months
|
Questionnaire measuring the direct and indirect costs
|
Assessed at 6 weeks, 3 months, 4.5 months, 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Bryan Tan, Tan Tock Seng Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2016/01241
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .